These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 20973713)

  • 1. Symptom improvement and residual symptoms during acute antidepressant treatment in pediatric major depressive disorder.
    Tao R; Emslie GJ; Mayes TL; Nakonezny PA; Kennard BD
    J Child Adolesc Psychopharmacol; 2010 Oct; 20(5):423-30. PubMed ID: 20973713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early prediction of acute antidepressant treatment response and remission in pediatric major depressive disorder.
    Tao R; Emslie G; Mayes T; Nakonezny P; Kennard B; Hughes C
    J Am Acad Child Adolesc Psychiatry; 2009 Jan; 48(1):71-8. PubMed ID: 19057412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of various methods of measuring antidepressant medication adherence among children and adolescents with major depressive disorder in a 12-week open trial of fluoxetine.
    Nakonezny PA; Hughes CW; Mayes TL; Sternweis-Yang KH; Kennard BD; Byerly MJ; Emslie GJ
    J Child Adolesc Psychopharmacol; 2010 Oct; 20(5):431-9. PubMed ID: 20973714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluoxetine treatment of depressed patients with comorbid anxiety disorders.
    Sonawalla SB; Farabaugh A; Johnson MW; Morray M; Delgado ML; Pingol MG; Rosenbaum JF; Fava M
    J Psychopharmacol; 2002 Sep; 16(3):215-9. PubMed ID: 12236627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of fluoxetine remission for hospitalized patients with major depressive disorder.
    Lin CH; Lane HY; Chen CC; Juo SH; Yen CF
    Psychiatry Clin Neurosci; 2011 Aug; 65(5):510-7. PubMed ID: 21851460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antidepressant response and well-being in pre-, peri- and postmenopausal women with major depressive disorder treated with fluoxetine.
    Cassano P; Soares CN; Cusin C; Mascarini A; Cohen LS; Fava M
    Psychother Psychosom; 2005; 74(6):362-5. PubMed ID: 16244512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Residual symptoms after remission of major depressive disorder with fluoxetine and risk of relapse.
    Iovieno N; van Nieuwenhuizen A; Clain A; Baer L; Nierenberg AA
    Depress Anxiety; 2011 Feb; 28(2):137-44. PubMed ID: 21284066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psychosocial functioning during the treatment of major depressive disorder with fluoxetine.
    Papakostas GI; Petersen T; Denninger JW; Tossani E; Pava JA; Alpert JE; Nierenberg AA; Fava M
    J Clin Psychopharmacol; 2004 Oct; 24(5):507-11. PubMed ID: 15349006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The relationship between early changes in the HAMD-17 anxiety/somatization factor items and treatment outcome among depressed outpatients.
    Farabaugh A; Mischoulon D; Fava M; Wu SL; Mascarini A; Tossani E; Alpert JE
    Int Clin Psychopharmacol; 2005 Mar; 20(2):87-91. PubMed ID: 15729083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The relationship between symptom relief and functional improvement during acute fluoxetine treatment for patients with major depressive disorder.
    Lin CH; Chou LS; Chen MC; Chen CC
    J Affect Disord; 2015 Aug; 182():115-20. PubMed ID: 25985380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maternal depressive symptoms in pediatric major depressive disorder: relationship to acute treatment outcome.
    Kennard BD; Hughes JL; Stewart SM; Mayes T; Nightingale-Teresi J; Tao R; Carmody T; Emslie GJ
    J Am Acad Child Adolesc Psychiatry; 2008 Jun; 47(6):694-699. PubMed ID: 18434919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report.
    Nierenberg AA; Husain MM; Trivedi MH; Fava M; Warden D; Wisniewski SR; Miyahara S; Rush AJ
    Psychol Med; 2010 Jan; 40(1):41-50. PubMed ID: 19460188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ECT Has Greater Efficacy Than Fluoxetine in Alleviating the Burden of Illness for Patients with Major Depressive Disorder: A Taiwanese Pooled Analysis.
    Lin CH; Huang CJ; Chen CC
    Int J Neuropsychopharmacol; 2018 Jan; 21(1):63-72. PubMed ID: 29228200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors and Moderators of Relapse in Children and Adolescents With Major Depressive Disorder.
    Kennard BD; Mayes TL; Chahal Z; Nakonezny PA; Moorehead A; Emslie GJ
    J Clin Psychiatry; 2018; 79(2):. PubMed ID: 29474007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early improvement in HAMD-17 and HAMD-7 scores predict response and remission in depressed patients treated with fluoxetine or electroconvulsive therapy.
    Lin CH; Park C; McIntyre RS
    J Affect Disord; 2019 Jun; 253():154-161. PubMed ID: 31035216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relationship between serum folate, vitamin B12, and homocysteine levels in major depressive disorder and the timing of improvement with fluoxetine.
    Papakostas GI; Petersen T; Lebowitz BD; Mischoulon D; Ryan JL; Nierenberg AA; Bottiglieri T; Alpert JE; Rosenbaum JF; Fava M
    Int J Neuropsychopharmacol; 2005 Dec; 8(4):523-8. PubMed ID: 15877935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder.
    Garakani A; Martinez JM; Marcus S; Weaver J; Rickels K; Fava M; Hirschowitz J
    Int Clin Psychopharmacol; 2008 Sep; 23(5):269-75. PubMed ID: 18703936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of adding cognitive therapy to fluoxetine dose increase on risk of relapse and residual depressive symptoms in continuation treatment of major depressive disorder.
    Perlis RH; Nierenberg AA; Alpert JE; Pava J; Matthews JD; Buchin J; Sickinger AH; Fava M
    J Clin Psychopharmacol; 2002 Oct; 22(5):474-80. PubMed ID: 12352270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trajectories of individual symptoms in remitters versus non-remitters with depression.
    Sakurai H; Uchida H; Abe T; Nakajima S; Suzuki T; Pollock BG; Sato Y; Mimura M
    J Affect Disord; 2013 Nov; 151(2):506-513. PubMed ID: 23886402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluoxetine once every third day in the treatment of major depressive disorder.
    Tural U; Onder E
    Eur Arch Psychiatry Clin Neurosci; 2003 Dec; 253(6):307-12. PubMed ID: 14714120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.